Abstract: An electrical connector includes: an insulative housing; and plural contacts secured to the insulative housing, each contact having a generally U-shaped part and a soldering part, the U-shaped part having a first contacting portion, a second contacting portion, and a connecting portion between the first contacting portion and the second contacting portion, wherein each of the first and second contacting portions has an outer contacting face, and one of the first and second contacting portions extends from the connecting portion to incline toward the other contacting portion.

Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.

Abstract: An electrical connector includes: an insulative housing having a base portion and a tongue portion extending forwardly from the base portion, the tongue portion having a plurality of terminal-receiving slots, a respective separating wall being disposed between every two neighboring terminal-receiving slots, at least one separating wall having an extending portion extending backwardly along an insertion direction to be located behind respective rear ends of the other separating walls; a number of terminals retained in the insulative housing and including a row of first contacts, each first contact having a pair of gaps located forwardly of the extending portion along the insertion direction; a metallic shielding plate retained in the insulative housing; and a shielding shell attached to the insulative housing.

Abstract: An electrical connector includes: an insulative housing having a base portion and a tongue portion extending forwardly from the base portion, the tongue portion having a plurality of terminal-receiving slots, a respective separating wall being disposed between every two neighboring terminal-receiving slots, at least one separating wall having an extending portion extending backwardly along an insertion direction to be located behind respective rear ends of the other separating walls; a number of terminals retained in the insulative housing and including a row of first contacts, each first contact having a pair of gaps located forwardly of the extending portion along the insertion direction; a metallic shielding plate retained in the insulative housing; and a shielding shell attached to the insulative housing.

Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.

Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least Cone compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.

Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least Cone compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.